About ReCode Therapeutics
ReCode Therapeutics is a company based in Menlo Park (United States) founded in 2015 by Daniel J Siegwart and Philip Thomas.. ReCode Therapeutics has raised $371 million across 7 funding rounds from investors including Amgen, Pfizer and Orbimed. ReCode Therapeutics offers products and services including SORT LNP Platform and Therapeutics Pipeline. ReCode Therapeutics operates in a competitive market with competitors including aTyr Pharma, InterMune, GEn1E, Pulmatrix and Verona Pharma, among others.
- Headquarter Menlo Park, United States
- Founders Daniel J Siegwart, Philip Thomas
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Recode Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$371 M (USD)
in 7 rounds
-
Latest Funding Round
$29 M (USD), Series B
Sep 29, 2025
-
Investors
Amgen
& 18 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ReCode Therapeutics
ReCode Therapeutics offers a comprehensive portfolio of products and services, including SORT LNP Platform and Therapeutics Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables targeted delivery of genetic medicines to specific organs
Develops mRNA and gene correction therapies for rare diseases
Unlock access to complete
Unlock access to complete
Funding Insights of ReCode Therapeutics
ReCode Therapeutics has successfully raised a total of $371M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $29 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $29.0M
-
First Round
First Round
(08 Feb 2019)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series B - ReCode Therapeutics | Valuation |
investors |
|
| Sep, 2023 | Amount | Series B - ReCode Therapeutics | Valuation | Solasta Ventures , Bioluminescence Ventures | |
| Jan, 2023 | Amount | Series B - ReCode Therapeutics | Valuation | Cystic Fibrosis Foundation |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ReCode Therapeutics
ReCode Therapeutics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Pfizer and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Founded Year | Domain | Location | |
|
A venture capital firm focused on biotechnology innovations.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ReCode Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ReCode Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Recode Therapeutics Comparisons
Competitors of ReCode Therapeutics
ReCode Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, InterMune, GEn1E, Pulmatrix and Verona Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| domain | founded_year | HQ Location |
Respiratory disease drugs for asthma and COPD are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Recode Therapeutics
Frequently Asked Questions about ReCode Therapeutics
When was ReCode Therapeutics founded?
ReCode Therapeutics was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Where is ReCode Therapeutics located?
ReCode Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Who is the current CEO of ReCode Therapeutics?
Shehnaaz Suliman is the current CEO of ReCode Therapeutics.
Is ReCode Therapeutics a funded company?
ReCode Therapeutics is a funded company, having raised a total of $371M across 7 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Feb 08, 2019.
What does ReCode Therapeutics do?
ReCode Therapeutics was founded in 2015 and is based in Menlo Park, United States. Precision medicines targeting lung-related diseases are developed, with a focus on the biotech sector. The pipeline features programs for primary ciliary dyskinesia and nonsense mutations in cystic fibrosis. A proprietary non-viral lipid nanoparticle platform is employed to deliver nucleic acid and protein payloads, enabling organ-specific targeting through systemic and local administration routes.
Who are the top competitors of ReCode Therapeutics?
ReCode Therapeutics's top competitors include aTyr Pharma, Pulmatrix and GEn1E.
What products or services does ReCode Therapeutics offer?
ReCode Therapeutics offers SORT LNP Platform and Therapeutics Pipeline.
Who are ReCode Therapeutics's investors?
ReCode Therapeutics has 19 investors. Key investors include Amgen, Pfizer, Orbimed, Cystic Fibrosis Foundation, and Tekla Capital Management.
What is ReCode Therapeutics's valuation?
The valuation of ReCode Therapeutics is $372M as of Oct 2021.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.